Active	Status	Sponsor type	Region	Phase	Filter
6 Active 0 Inactive 6 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes: « June » « 2025 » M T W T F S S 26 27 28 29 30 31 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 1 2 3 4 5 6   - « June » « 2025 » M T W T F S S 26 27 28 29 30 31 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 1 2 3 4 5 6   Show only changed items Enrollment:

Advanced Filters

6 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Guerra, Ixiu del Carmen Cabrales
NCT05099640 / 2021-000474-29: A Study of PTC923 in Participants With Phenylketonuria	Completed	3	157	Europe, Canada, US, RoW	PTC923, Placebo	PTC Therapeutics	Phenylketonuria	04/23	05/23
NCT05166161 / 2021-000497-28: A Long-Term Safety Study of PTC923 in Participants With Phenylketonuria	Recruiting	3	200	Europe, Canada, Japan, US, RoW	PTC923, Sepiapterin	PTC Therapeutics	Phenylketonuria	04/26	04/26
REBUILD-2, NCT04616326 / 2018-004622-28: A Study of Galcanezumab (LY2951742) in Participants 12 to 17 Years of Age With Chronic Migraine	Recruiting	3	300	Europe, Japan, US, RoW	Galcanezumab, LY2951742, Placebo	Eli Lilly and Company	Chronic Migraine	07/25	03/26
REBUILD, NCT03432286 / 2017-004351-23: A Study of Galcanezumab (LY2951742) in Participants 6 to 17 Years of Age With Episodic Migraine	Recruiting	3	325	Europe, Japan, US, RoW	Galcanezumab, LY2951742, Placebo	Eli Lilly and Company	Episodic Migraine	11/25	11/26
PIONEER-PEDS1, NCT04396236 / 2019-004378-24: A Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine	Recruiting	3	1633	Europe, Japan, US, RoW	Lasmiditan, LY573144, Placebo	Eli Lilly and Company	Migraine	11/26	11/26
PIONEER-PEDS2, NCT04396574 / 2019-004379-38: A 12-Month Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine	Recruiting	3	1000	Europe, Japan, US, RoW	Lasmiditan, LY573144	Eli Lilly and Company	Migraine	01/28	01/28

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Guerra, Ixiu del Carmen Cabrales
NCT05099640 / 2021-000474-29: A Study of PTC923 in Participants With Phenylketonuria	Completed	3	157	Europe, Canada, US, RoW	PTC923, Placebo	PTC Therapeutics	Phenylketonuria	04/23	05/23
NCT05166161 / 2021-000497-28: A Long-Term Safety Study of PTC923 in Participants With Phenylketonuria	Recruiting	3	200	Europe, Canada, Japan, US, RoW	PTC923, Sepiapterin	PTC Therapeutics	Phenylketonuria	04/26	04/26
REBUILD-2, NCT04616326 / 2018-004622-28: A Study of Galcanezumab (LY2951742) in Participants 12 to 17 Years of Age With Chronic Migraine	Recruiting	3	300	Europe, Japan, US, RoW	Galcanezumab, LY2951742, Placebo	Eli Lilly and Company	Chronic Migraine	07/25	03/26
REBUILD, NCT03432286 / 2017-004351-23: A Study of Galcanezumab (LY2951742) in Participants 6 to 17 Years of Age With Episodic Migraine	Recruiting	3	325	Europe, Japan, US, RoW	Galcanezumab, LY2951742, Placebo	Eli Lilly and Company	Episodic Migraine	11/25	11/26
PIONEER-PEDS1, NCT04396236 / 2019-004378-24: A Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine	Recruiting	3	1633	Europe, Japan, US, RoW	Lasmiditan, LY573144, Placebo	Eli Lilly and Company	Migraine	11/26	11/26
PIONEER-PEDS2, NCT04396574 / 2019-004379-38: A 12-Month Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine	Recruiting	3	1000	Europe, Japan, US, RoW	Lasmiditan, LY573144	Eli Lilly and Company	Migraine	01/28	01/28